Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Nov. 12, 2013, 237 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $356,344,136.36. Highlighted Stocks Traded by Insiders: West Pharmaceutical Services (WST) - FREE Research Report Lennartz Heino who is President Europe at West Pharmaceutical Services sold 5,102 shares at $46.70 on Nov. 12, 2013. Following this transaction, the President Europe owned 18,961 shares meaning that the stake was reduced by 21.2% with the 5,102 share transaction. The shares most recently traded at $46.79, up $0.09, or 0.19% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:
4-Week # shares sold: 15,200
12-Week # shares sold: 27,083
24-Week # shares sold: 30,083
The average volume for West Pharmaceutical Services has been 257,200 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.3 billion and is part of the health care sector and health services industry. Shares are up 71.14% year to date as of the close of trading on Tuesday. West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.86%. The company has a P/E ratio of 30.2. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on WST - FREETheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.